Misyo (Methadone Hydrochloride)

Methadone, the active ingredient in Misyo, is an opioid analgesic presented as an oral formulation for oral use. It is employed in the maintenance treatment of opioid dependence and for management of severe chronic pain in adult patients. Methadone acts as a full agonist at the mu‑opioid receptor, providing stable plasma concentrations that reduce withdrawal symptoms and control pain while allowing patients to stabilize their daily activities.

GNH USA supplies Misyo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and procurement teams worldwide.

Methadone is used in opioid‑receptor mediated conditions, primarily for dependence and pain management. - Opioid dependence: provides maintenance therapy that reduces withdrawal symptoms and cravings, supporting long‑term recovery. - Severe chronic pain: offers long‑acting analgesia for patients requiring opioid treatment when other options are insufficient. - Supervised detoxification: assists in controlled tapering of opioid use under medical supervision.

Methadone may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Constipation: reduced bowel motility. - Drowsiness: increased sleepiness or fatigue. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Respiratory depression: slowed breathing that can be life‑threatening. - QT interval prolongation: risk of cardiac arrhythmias. - Seizures: rare neurologic events. - Severe hypotension: marked drop in blood pressure. - Cardiac arrhythmia: irregular heart rhythm.

When prescribing or dispensing Misyo, several safety considerations are essential. - Cardiac assessment: evaluate QT interval and correct electrolyte imbalances. - Respiratory monitoring: observe for signs of depressed breathing, especially during initiation. - Liver function: assess hepatic status as metabolism may be impaired. - Renal function: adjust use in patients with significant renal impairment. - Discontinuation: avoid abrupt cessation to prevent precipitated withdrawal. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Methadone interacts with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid): - CNS depressants (e.g., benzodiazepines, barbiturates): risk of profound respiratory depression. - MAO inhibitors: can precipitate severe hypertension or serotonin syndrome. - QT‑prolonging agents (e.g., certain antiarrhythmics, antipsychotics): increase risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise methadone levels. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may lower methadone concentrations. - Certain antiretrovirals (e.g., protease inhibitors): require dose adjustments and close monitoring.